Protara Therapeutics Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
27
- Stock Symbol
-
TARA
- Investments
-
1
- Share Price
-
$1.69
- (As of Wednesday Closing)
Protara Therapeutics General Information
Description
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Contact Information
Website
www.protaratx.comCorporate Office
- 345 Park Avenue South
- 3rd Floor
- New York, NY 10010
- United States
Corporate Office
- 345 Park Avenue South
- 3rd Floor
- New York, NY 10010
- United States
Protara Therapeutics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.69 | $1.73 | $1.04 - $5.24 | $35.1M | 20.6M | 168K | -$3.03 |
Protara Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (7,169) | (47,022) | (59,517) | (10,474) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (43,873) | (43,260) | (66,797) | (47,372) |
| Net Income | (40,689) | (40,420) | (65,952) | (47,252) |
| Total Assets | 101,647 | 78,954 | 113,290 | 172,596 |
| Total Debt | 4,984 | 5,467 | 6,384 | 7,239 |
Protara Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Protara Therapeutics Comparisons
Industry
Financing
Details
000000
00000
Protara Therapeutics Competitors (98)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sernova | Corporation | London, Canada | 00 | 000.00 | 000000000 | 000.00 |
| Ember Therapeutics | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
| Adimab | Venture Capital-Backed | Lebanon, NH | 000 | 00000 | 0000000000 0 | 00000 |
Protara Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Protara Therapeutics Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Jesse Shefferman | Co-Founder, Chief Executive Officer & Board Member | |
| Patrick Fabbio | Chief Financial Officer, Finance | |
| Kristy Rosse | Senior Vice President & Chief People Officer | |
| Jacqueline Zummo | Co-Founder, Chief Scientific Operations Officer & Senior Vice President | |
| Justine O'Malley | Vice President, Investor Relations & Communications |
Protara Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barry Flannelly | Self | Board Member | 000 0000 |
| Cynthia Smith | Self | Director | 000 0000 |
| Gregory Sargen | Self | Board Member | 000 0000 |
| Jane Huang MD | Self | Board Member | 000 0000 |
| Luke Beshar | Self | Chairman | 000 0000 |
Protara Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Protara Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Protara Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Proteon Therapeutics | 09-Jan-2020 | 0000000000 | 000.00 | Pharmaceuticals |
Protara Therapeutics ESG
Risk Overview
Risk Rating
Updated January, 26, 2021
40.54 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 452
Rank
Percentile
Protara Therapeutics FAQs
-
When was Protara Therapeutics founded?
Protara Therapeutics was founded in 2006.
-
Who is the founder of Protara Therapeutics?
Jesse Shefferman, Jacqueline Zummo, and Randall Marshall MD are the founders of Protara Therapeutics.
-
Who is the CEO of Protara Therapeutics?
Jesse Shefferman is the CEO of Protara Therapeutics.
-
Where is Protara Therapeutics headquartered?
Protara Therapeutics is headquartered in New York, NY.
-
What is the size of Protara Therapeutics?
Protara Therapeutics has 27 total employees.
-
What industry is Protara Therapeutics in?
Protara Therapeutics’s primary industry is Drug Discovery.
-
Is Protara Therapeutics a private or public company?
Protara Therapeutics is a Public company.
-
What is Protara Therapeutics’s stock symbol?
The ticker symbol for Protara Therapeutics is TARA.
-
What is the current stock price of Protara Therapeutics?
As of 11-Sep-2024 the stock price of Protara Therapeutics is $1.69.
-
What is the current market cap of Protara Therapeutics?
The current market capitalization of Protara Therapeutics is $35.1M.
-
Who are Protara Therapeutics’s competitors?
Sernova, Ember Therapeutics, NexImmune, TScan Therapeutics, and Adimab are some of the 98 competitors of Protara Therapeutics.
-
What is Protara Therapeutics’s annual earnings per share (EPS)?
Protara Therapeutics’s EPS for 12 months was -$3.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
